AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
By Adria CalatayudAstraZeneca said its new breast-cancer pill missed the key goal of slowing the disease from worsening in a late-stage clinical trial.The U.K. drugmaker evaluated its Etcamah medicine, in combination with Pfizer's Ibrance, as a first-line treatment for patients with a type of advan…